Digitoxin (Crystodigin)

Category:

  • Cardiac

Description:

  • Antidysrhythmic; cardiac glycoside

Indications:

  • Congestive heart failure, atrial fibrillation, atrial flutter

  • Paroxysmal atrial tachycardia (PAT)

  • Cardiogenic shock

Contraindications:

  • Ventricular tachycardia

  • Ventricular fibrillation

Precautions:

  • Pregnancy category C; passes readily into fetus; excretion into breast milk unknown

  • Hypokalemia, hypomagnesemia, hypercalcemia, hypothyroidism, sick sinus syndrome

  • Severe pulmonary disease, hepatic disease, AV block, acute MI, hepatic disease

  • Wolff-Parkinson-White syndrome

Adverse Reactions (Side Effects):

  • CNS: anorexia, apathy, confusion, delirium, disorientation, drowsiness, EEG abnormalities, hallucinations, headache, mental depression, neuralgia, psychosis, restlessness, seizures, weakness

  • CV: atrial fibrillation, AV block, bradycardia, premature ventricular contractions (PVC’s), ventricular fibrillation, ventricular tachycardia

  • EENT: visual disturbances (blurred, yellow or green halo effect)

  • GI: abdominal discomfort, diarrhea, hemorrhagic necrosis of the intestines, nausea, vomiting

  • HEME: eosinophilia, thrombocytopenia

  • SKIN: rash

Dosage:

Administered orally (tablet)

  • Adult:            Loading dose PO (rapid) 0.6mg, followed by 0.4mg, then 0.2mg at every 4-6 hour intervals; (slow) 0.2mg 2 times daily for 4 days; maintenance dose PO 0.05-0.3mg daily.  Dosage reduction not needed in renal function impairment

  • Child:             Loading dose PO <1 year 0.045 mg/kg, 1-2 years 0.04 mg/kg, >2 years 0.03 mg/kg divided into 3, 4, or more portions with >6 hours between doses; maintenance dose PO 1/10 loading dose

Drug interactions:

  • Alprazolam, amiodarone, diltiazem, verapamil, bepridil, nitrendipine, quinidine, carvedilol, cyclosporine, erythromycin and tetracycline (change in bacterial flora causing effect may persist for months), hydroxychloroquine, NSAIDS, azole antifungals, omeprazole, lansoprazole, propafenone, quinine, spironolactone, tacrolimus:  May cause increased digoxin levels

  • Charcoal: reduced digitalis levels

  • Beta-Blockers: Potentiation of bradycardia

  • Succinylcholine: increased arrhythmias

 

Special considerations:

  • Listed adverse effects are mostly signs of toxicity

  • When digitalis indicated digoxin is 1st line drug because of shorter ½-life and faster clearance in the event toxicity develops.

  • Rule out digitalis toxicity if nausea, vomiting, or arrhythmias develop

  • Therapeutic range: 9-25 ng/ml

 

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site